Multi-Center Phase 2 Open-Label Study To Evaluate Safety And Efficacy In Subjects With Melanoma Metastatic To The Brain Treated With Nivolumab In Combination With Ipilimumab Followed By Nivolumab Monotherapy
Brief description of study
If you have been diagnosed with metastatic melanoma that has spread to your brain, you may qualify to participate in a study investigating how well combined nivolumab (Opdivo) and ipilimumab (Yervoy), followed by nivolumab alone (monotherapy) work for the treatment of melanoma with brain metastases. The main goal of this phase 2 trial is to test the safety of the drug nivolumab (Opdovo™) in combination with ipilimumab (Yervoy™) followed by nivolumab alone (monotherapy) and to see how well it works for the treatment of melanoma with brain metastases.
Clinical Study Identifier: s14-01235
ClinicalTrials.gov Identifier: NCTs14-01235
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
